Literature DB >> 10665644

Epstein-Barr virus-encoded latent membrane protein 1 co-expresses with epidermal growth factor receptor in nasopharyngeal carcinoma.

T S Sheen1, Y T Huang, Y L Chang, J Y Ko, C S Wu, Y C Yu, C H Tsai, M M Hsu.   

Abstract

Latent membrane protein 1 (LMP-1) is the only Epstein-Barr virus (EBV)-encoded oncogenic protein that has been detected in nasopharyngeal carcinoma (NPC), a cancer that is closely associated with EBV. Previous in-vitro studies have demonstrated that LMP-1 can upregulate epidermal growth factor receptor (EGFR) in epithelial cells. It was not established whether this cellular effect exists in NPC. To assess the association between LMP-1 and EGFR in NPC tissues, 60 NPC specimens were examined by immunohistochemistry using anti-LMP-1 antibody (CS 1-4) and anti-EGFR antibodies (EGFR 1, EGFR 1005). The results revealed that 41 (68.3%) specimens were immunopositive for LMP-1 and 44 (73.3%) specimens over-expressed EGFR. Morphologically, the expressions of LMP-1 and EGFR were homogeneously distributed in the tumor nests. In addition, the correlation between LMP-1 and EGFR was statistically significant (P<0.001, chi2 test, d.f. = 1). To elucidate further the correlation between LMP-1 and EGFR in vivo and in situ, an indirect dual immunofluorescence assay was conducted, using secondary antibodies conjugated with fluorescein isothiocyanate (FITC) or indocarbocyanine (Cy3). The results disclosed an intimate co-expression of LMP-1 and EGFR. In summary, the data indicate that over-expression of EGFR is a common phenomenon in NPC, and that EGFR is co-expressed with LMP-1 in NPC. Thus, EBV may play a role in the tumorigenesis of NPC through the effects of LMP-1 and EGFR.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10665644      PMCID: PMC5926033          DOI: 10.1111/j.1349-7006.1999.tb00710.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  38 in total

1.  Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells.

Authors:  L J Old; E A Boyse; H F Oettgen; E D Harven; G Geering; B Williamson; P Clifford
Journal:  Proc Natl Acad Sci U S A       Date:  1966-12       Impact factor: 11.205

2.  Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens.

Authors:  T C Wu; R B Mann; J I Epstein; E MacMahon; W A Lee; P Charache; S D Hayward; R J Kurman; G S Hayward; R F Ambinder
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

3.  Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells.

Authors:  M Rowe; H S Evans; L S Young; K Hennessy; E Kieff; A B Rickinson
Journal:  J Gen Virol       Date:  1987-06       Impact factor: 3.891

Review 4.  Growth factors in development, transformation, and tumorigenesis.

Authors:  M Cross; T M Dexter
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

5.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells.

Authors:  D Wang; D Liebowitz; E Kieff
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

6.  Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.

Authors:  F Wang; C Gregory; C Sample; M Rowe; D Liebowitz; R Murray; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

7.  Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines.

Authors:  Y H Xu; N Richert; S Ito; G T Merlino; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

8.  Epstein-Barr virus gene expression in nasopharyngeal carcinoma.

Authors:  L S Young; C W Dawson; D Clark; H Rupani; P Busson; T Tursz; A Johnson; A B Rickinson
Journal:  J Gen Virol       Date:  1988-05       Impact factor: 3.891

9.  Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells.

Authors:  G T Merlino; S Ishii; J Whang-Peng; T Knutsen; Y H Xu; A J Clark; R H Stratton; R K Wilson; D P Ma; B A Roe; John Hunts; Nobuyoshi Shimizu; Ira Pastan
Journal:  Mol Cell Biol       Date:  1985-07       Impact factor: 4.272

10.  Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia.

Authors:  R Pathmanathan; U Prasad; G Chandrika; R Sadler; K Flynn; N Raab-Traub
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

View more
  8 in total

1.  Dysregulation of HER2/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells.

Authors:  Jiun-Han Lin; Ching-Hwa Tsai; Jan-Show Chu; Jeou-Yuan Chen; Kenzo Takada; Jin-Yuh Shew
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

2.  Expression of Epstein-Barr virus (EBV)-encoded latent membrane proteins and STAT3 activation in nasopharyngeal carcinoma.

Authors:  Maike Buettner; Nicole Heussinger; Gerald Niedobitek
Journal:  Virchows Arch       Date:  2006-10-11       Impact factor: 4.064

Review 3.  The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  Chi Man Tsang; Sai Wah Tsao
Journal:  Virol Sin       Date:  2015-04-21       Impact factor: 4.327

4.  Nasopharyngeal carcinoma signaling pathway: an update on molecular biomarkers.

Authors:  Warut Tulalamba; Tavan Janvilisri
Journal:  Int J Cell Biol       Date:  2012-03-05

5.  Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study.

Authors:  Xue-Song Sun; Yu-Jing Liang; Xiao-Yun Li; Sai-Lan Liu; Qiu-Yan Chen; Lin-Quan Tang; Hai-Qiang Mai
Journal:  Drug Des Devel Ther       Date:  2019-09-10       Impact factor: 4.162

6.  Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: A single-center, retrospective study.

Authors:  Naohiro Takeshita; Tomohiro Enokida; Susumu Okano; Takao Fujisawa; Akihisa Wada; Masanobu Sato; Hideki Tanaka; Nobukazu Tanaka; Atsushi Motegi; Sadamoto Zenda; Tetsuo Akimoto; Makoto Tahara
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

7.  In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.

Authors:  Cong Xue; Ying Tian; Jing Zhang; Yuanyuan Zhao; Jianhua Zhan; Wenfeng Fang; Li Zhang
Journal:  Drug Des Devel Ther       Date:  2016-03-31       Impact factor: 4.162

8.  Polyethylene Glycol-Coated Graphene Oxide Loaded with Erlotinib as an Effective Therapeutic Agent for Treating Nasopharyngeal Cancer Cells.

Authors:  Ming-Ying Lan; Yen-Bin Hsu; Ming-Chin Lan; Jyh-Ping Chen; Yu-Jen Lu
Journal:  Int J Nanomedicine       Date:  2020-10-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.